middelenmisbruik, afhankelijkheid androgen abuse use of anabolic steroids
Conditions
Interventions
See 'study design'.
Sponsors
Elisabeth-Tweesteden ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Men of at least 18 years old. • The subjects intents to start an androgen cycle within 2 weeks after enrollment. • The planned cycle has an average weekly dose >250 mg and duration >6 weeks.
Exclusion criteria
Exclusion criteria: • The use of AAS in the 3 months prior to enrollment (except for TRT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • The effect of a harm reduction strategy on the duration of exposure to AAS by amateur athletes in a 12 month study period. • The effect of a one-time online consultation about diet and training regimens on the duration of exposure to AAS in a 12 month study period. • The extent to which providing a harm reduction intervention leads to a different amount of new users of AAS. • The prevalence of obstructive sleep apnea syndrome during AAS use. • The prevalence of non-alcoholic fatty liver disease during AAS use. | — |
Secondary
| Measure | Time frame |
|---|---|
| • The effect of a harm reduction strategy on the duration of growth hormone use and the number of times post-cycle therapy is employed in a 12 month study period. • The extent to which the different user typologies predict the effectiveness of the harm reduction strategy.. • The incidence of serious adverse events during or after AAS use. | — |
Countries
Netherlands
Outcome results
None listed